Newly detected serum M-protein

**STEP 1 (Immunology Laboratory)**
Further Immunology investigations performed:
- Identification of serum M-protein isotype
- Quantification of serum M-protein
- Serum immunoglobulin levels
- Screen for serum free light chains (SFLC)
- Screen for Bence-Jones protein (if urine provided)

**STEP 2 (Clinician)**
Ensure the following investigations are carried out:
- Spot urine for urinary protein excretion and urinary protein electrophoresis
- Full blood count
- Serum creatinine
- Urea and electrolytes
- Corrected serum calcium

**STEP 3 (Clinician)**
Are there any symptoms or physical signs suggestive of:
- Myeloma, other lymphoproliferative disorders or light chain amyloidosis

Asymptomatic but unexplained incidental abnormal investigations (laboratory or imaging) such as:
- anaemia, hypercalcaemia, renal impairment, lytic lesions or osteoporosis on X-rays

Refer to Haematology for further investigation and management

Immunology will inform the Haematology Myeloma Team

Lifelong monitoring of the patient is required:
- Follow up patient every 3-4 months for the 1st year
- Extend follow up to every 6-12 months if asymptomatic and laboratory markers are stable

Follow up appointment:
- Examine the patient for symptoms or physical signs suggestive of underlying plasma cell or lymphoproliferative disorder
- Ensure the following laboratory markers are measured:
  - Quantification of M-protein and serum immunoglobulins
  - Full blood count
  - Serum creatinine
  - Urea and electrolytes
  - Corrected serum calcium

Are any of the following criteria met?
- M-protein concentration has increased by ≥ 25% (min absolute increase of 5g/L)
- Development of symptoms compatible with an underlying plasma cell or lymphoproliferative disorder
- Development of unexplained anaemia, other cytopenias, abnormal renal function or hypercalcaemia
Guidance Notes

- It is the responsibility of the patient’s Clinician to ensure that steps 2 and 3 are carried out
- For more detailed information please refer to our guidance for users: *Investigation of newly detected M-proteins and management of monoclonal gammopathy of undetermined significance (MGUS)*
- For blood sample requirements please refer to the *pathology test directory*